GH Research jumps after FDA lifts clinical hold on depression drug trials

GH Research

05/01/2026 13:27

** Shares of GH Research GHRS.O rise 45% to $19.18 premarket

** U.S. Food and Drug Administration lifts its clinical hold on GHRS' experimental depression drug, GH001, allowing company to enroll U.S. patients in trials

** Co plans to meet with health regulator to finalize design of its global late-stage program

** Co plans late-stage trials to begin this year

** GHRS rose 60.6% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))